The U.S. Meals and Drug Administration has delayed a gathering a few COVID-19 vaccine for kids youthful than 5 that was initially scheduled to happen subsequent week, elevating questions on once they'll be capable of get vaccinated in opposition to the lethal virus. The FDA stated it desires to see extra information from Pfizer earlier than continuing.
Children youthful than 5 are the solely age group within the U.S. that can't but get the vaccine. Given the current rise in youngster hospitalizations amid the Omicron surge, an knowledgeable panel was anticipated to satisfy on February 15 and determine if children below 5 ought to begin getting Pfizer's vaccine in two doses — earlier than information on a 3rd potential dose was evaluated.
However now, the FDA stated it believes "further info relating to the continuing analysis of a 3rd dose must be thought of."
The delays provides the company time to think about the extra information, "permitting for a clear public dialogue as a part of our regular scientific and regulatory processes for COVID-19 vaccines."
"We are going to present an replace on timing for the advisory committee assembly as soon as we obtain further information on a 3rd dose on this age group from the corporate's ongoing scientific trial and have a possibility to finish an up to date analysis," the FDA stated in an announcement.
Pfizer and BioNTech stated they count on to have information on three vaccine doses in early April.
Early information from Pfizer confirmed that two low doses of its COVID vaccine, whereas secure, did not provide sufficient immunity in opposition to the virus for teenagers of preschool age, the 2- to 4-year-olds.
Contributing: The Related Press